Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company has reported that its Anti-IL-17 monoclonal antibody, Ixekizumab, met primary endpoint in Phase II study in patients with chronic plaque psoriasis.
Subscribe to our email newsletter
The study reported that significantly more patients achieved at least a 75% improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.
A PASI 75 response in a patient represents a 75% reduction of PASI scores from baseline.
Secondary endpoints included an evaluation of the percentage of patients achieving at least 90% and 100% improvement in PASI (PASI 90 or PASI 100) at week 12.
In patients treated with ixekizumab, the percentages of patients achieving a PASI 90 response were 71%, 59% and 50%, which were significantly higher than with placebo (0%).
PASI 100 responses were significantly better at the 150mg dose and 75mg dose when compared with placebo (0%).
PASI 100 responses at the 25mg and 10mg doses were not significantly greater than placebo, nor was the PASI 90 response at the 10mg dose, the study reported.
Lilly autoimmune product development vice president Eiry Roberts said the company developed ixekizumab in its research labs and it is being studied in Phase III for psoriasis.